About the Study: Cardiology practitioners need to remain updated on rapidly evolving breast cancer therapies to care for this growing, unique patient population. The field of cardio-oncology has evolved to address the cardiovascular needs of patients and survivors.

Corresponding Author: Rina Mauricio, MD, Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, 2001 Inwood Rd, Dallas, TX 75390 (rina.mauricio@utsouthwestern.edu).

10.1001/jamacardio.2026.2546

To access the embargoed study: Visit our JAMA Network Media Center website at this link

Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Editor’s Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Journal

JAMA Cardiology

Cardiac cachexia represents a severe decline in heart muscle mass and function, observed in patients with advanced cancer, notably those afflicted by lung adenocarcinoma. Unlike conventional manifestations of heart disease, cardiac cachexia involves a multifaceted cascade of molecular alterations orchestrated by tumor-host interactions. The research team employed state-of-the-art transcriptomic and proteomic profiling techniques to map these alterations in affected cardiac tissue, revealing a distinct signature linked to tumor-derived factors.

At the molecular level, lung adenocarcinoma appears to trigger a systemic inflammatory response that profoundly impacts myocardial metabolism and structural integrity. Key mediators such as pro-inflammatory cytokines and tumor-derived exosomes were identified as pivotal agents inciting myocardial atrophy. These bioactive molecules disrupt calcium homeostasis, mitochondrial function, and redox balance within cardiomyocytes, ultimately compromising cardiac output and fostering progressive heart failure.

Intriguingly, the study revealed an unexpected upregulation of specific microRNAs (miRNAs) in the myocardium of cancer-bearing subjects. These miRNAs modulate gene expression networks responsible for muscle protein synthesis and degradation, effectively tipping the balance towards proteolysis and cellular apoptosis. The elucidation of these miRNA profiles not only enhances our understanding of cardiac cachexia but also presents potential biomarkers for early detection and personalized interventions.

In addition to these transcriptomic insights, proteomic analyses uncovered alterations in energy metabolism pathways within the failing heart. Enzymes critical for fatty acid oxidation and oxidative phosphorylation were markedly downregulated, hinting at a metabolic reprogramming that favors catabolism over energy production. This metabolic shift parallels observations in skeletal muscle wasting associated with cachexia, reinforcing the systemic nature of cancer-induced catabolic states.

The interplay between lung adenocarcinoma-derived factors and cardiac tissue extends beyond mere inflammatory signaling. The researchers highlighted aberrant activation of ubiquitin-proteasome and autophagy-lysosome pathways in cardiac cells, mechanisms traditionally associated with protein quality control. The excessive activation of these catabolic pathways instigates accelerated degradation of structural proteins, exacerbating myocardial wasting.

Furthermore, mitochondrial dysfunction emerged as a central feature of cardiac cachexia in this context. The team documented impaired mitochondrial biogenesis and increased production of reactive oxygen species (ROS) within cardiomyocytes. This oxidative stress not only damages mitochondrial DNA but also amplifies apoptotic signaling cascades, cumulatively undermining cardiac cellular viability.

These molecular revelations carry profound clinical implications. Current management of cancer patients rarely addresses cardiac cachexia explicitly, leading to overlooked deterioration of cardiac health that significantly influences morbidity and mortality. With the identification of specific molecular signatures, there is now potential to develop targeted therapeutics aimed at mitigating heart muscle loss without impeding oncologic treatment efficacy.

Translational strategies emerging from this research may involve pharmacologic modulation of miRNA activity, cytokine blockade, and mitochondrial protection to preserve cardiac function in lung adenocarcinoma patients. Additionally, advanced imaging coupled with molecular biomarkers could facilitate earlier diagnosis of cardiac cachexia, enabling timely intervention before clinical heart failure ensues.

This research also underscores the necessity of integrative cardio-oncology care models that monitor cardiac function as an integral component of cancer management. Interdisciplinary collaboration between oncologists and cardiologists will be vital for implementing these molecular insights into clinical practice, improving patient outcomes through comprehensive surveillance and tailored treatment paradigms.

Another critical facet illuminated by the study involves the role of tumor microenvironment-derived exosomes. These extracellular vesicles serve as vehicles for transferring oncogenic signals to distant organs, including the heart. By unravelling the cargo profiles of these exosomes, the research paves the way for novel liquid biopsy approaches to detect early signs of cardiac involvement in lung cancer.

Moreover, the study’s findings prompt reevaluation of adjuvant therapies currently employed in oncology, some of which may exacerbate cardiac cachexia. A delicate balance must be struck between preserving antitumor efficacy and preventing collateral cardiac damage, highlighting the importance of molecularly guided treatment regimens.

The recognition of lung adenocarcinoma as a systemic disease impacting cardiac muscle challenges the traditional compartmentalization of oncology and cardiology. It calls for expanded research focusing on the crosstalk mechanisms at the molecular level that precipitate multi-organ involvement in cancer. Such insights hold promise for revolutionizing both cancer care and cardiology by bridging gaps between disciplines.

Looking forward, larger cohort studies and clinical trials will be imperative to validate these molecular signatures and translate them into standardized diagnostic panels and therapeutic targets. The integration of multi-omics data sets encompassing genomics, proteomics, and metabolomics will enhance the resolution of cardiac cachexia’s molecular landscape, fostering precision medicine in cardio-oncology.

In conclusion, the pioneering work by Fu and colleagues marks a significant leap in understanding how lung adenocarcinoma orchestrates cardiac cachexia through intricate molecular signatures. It highlights an urgent need to address cardiac complications in the cancer continuum, emphasizing molecular diagnostics and targeted therapeutics as pathways to improved survival and quality of life for patients facing the dual burden of cancer and heart disease. This comprehensive molecular portrait opens new horizons for cardio-oncology, inviting innovation and collaboration to combat this devastating syndrome.

Subject of Research: Molecular mechanisms of lung adenocarcinoma-driven cardiac cachexia in the field of cardio-oncology

Article Title: Cardio-oncology in focus: novel molecular signatures of lung adenocarcinoma-driven cardiac cachexia

Article References:
Fu, Z., Lin, Z., Chen, S. et al. Cardio-oncology in focus: novel molecular signatures of lung adenocarcinoma-driven cardiac cachexia. Med Oncol 42, 406 (2025). https://doi.org/10.1007/s12032-025-02933-9

Image Credits: AI Generated

The convergence of NHCS’s profound expertise in Asian cardiovascular health with Mayo Clinic’s unparalleled track record in medical innovation promises to unlock new frontiers in cardiovascular science. Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality worldwide, and addressing them demands a transdisciplinary approach that integrates diverse regional data sets, genetic backgrounds, and healthcare delivery models. This collaboration is fundamentally designed to create a dynamic knowledge exchange platform encouraging seamless cross-pollination of ideas, methods, and clinical practices between two of the world’s foremost cardiovascular institutions.

One of the cardinal focal points of the collaboration lies in the emerging field of cardio-oncology. This discipline recognizes the intricate interplay between cancer therapies and cardiovascular health, a concern that has gained heightened significance as advances in oncology prolong cancer patient survival. As certain chemotherapeutic agents and radiotherapy modalities carry a risk of cardiotoxicity, safeguarding patients’ cardiovascular function during and after cancer treatment has become a clinical imperative. By integrating cardiological expertise into oncological care pathways, NHCS and Mayo Clinic intend to pioneer clinical protocols, educational exchanges, and research initiatives that will better protect patients from therapy-induced cardiovascular complications.

Beyond cardio-oncology, the partners are uniting around the development of innovative healthcare solutions designed to transform cardiac treatment paradigms. Central to this endeavor is the utilization of novel biomarkers and digital imaging technologies, including the application of artificial intelligence (AI) to electrocardiograms (ECGs) and cardiac imaging. AI-enabled digital biomarkers represent a nuance shift, capturing subtle physiological signatures that may elude traditional diagnostic modalities. The NHCS’s richly annotated cardiovascular database of Asian populations, epitomized by insights from the SingHEART study—a comprehensive and multi-omic national longitudinal cohort—provides an unprecedented data reservoir for algorithm training and validation. This collaboration aims to refine AI tools ensuring they are accurate, safe, and reliable across ethnically diverse Asian cohorts, thus driving equitable healthcare delivery.

The increasing aging population worldwide highlights another research imperative embraced by the collaboration: understanding cardiovascular aging and frailty. Cardiovascular aging encompasses complex biological processes that predispose older individuals to increased morbidity and mortality. Through advanced imaging modalities and bio-digital markers, early detection and stratification of cardiovascular aging can facilitate personalized preventive and therapeutic interventions. The partnership aims to develop novel approaches to identify frailty and cardiovascular decline at a subclinical stage, combining molecular insights with functional assessments, potentially transforming how aging-related cardiovascular diseases are managed.

Underlying the partnership’s scientific ambitions is a commitment to translational research and academic development. NHCS and Mayo Clinic envisage co-developing shared intellectual property—including clinical protocols, therapeutic guidelines, and novel diagnostic technologies—tailored specifically to both Western and Asian patient populations. This recognition that “one size does not fit all” in medicine underscores the essentiality of culturally and genetically responsive healthcare solutions. Furthermore, the collaboration aspires to empower healthcare professionals globally through dedicated training programs, workshops, and educational exchanges designed to disseminate cutting-edge knowledge and enhance clinical competencies in cardiovascular medicine.

The technical breadth of the collaboration extends to exploring the integration of artificial intelligence not merely as a diagnostic adjunct but as a tool for predictive modeling and patient stratification. By harnessing machine learning algorithms capable of assimilating multi-dimensional datasets—including genomic, proteomic, imaging, and clinical parameters—the partnership members aim to pioneer predictive analytics that can preemptively identify patients at risk for adverse cardiovascular events and optimize treatment trajectories.

Professor Yeo Khung Keong, Chief Executive Officer of NHCS, articulated the critical need for such a collaboration: “Cardiovascular disease remains a leading health concern in Asia, with distinct epidemiological profiles compared to Western populations. Through this partnership, we aim to accelerate the development of solutions that address these unique challenges, fostering innovations that will benefit not only current patients but generations of healthcare professionals to come.” This statement captures the visionary scope of a collaboration designed to be transformative, far-reaching, and enduring.

From the Mayo Clinic side, leadership underscored the mutual benefits of this alliance. Professor Amir Lerman, Director of the Mayo Cardiovascular Research Centre, echoed his enthusiasm for the joint venture, emphasizing the shared commitment to advancing cardiovascular health worldwide. He highlighted the importance of integrating advanced analytics and cross-population data validation to ensure that innovations born from this partnership will meet global standards of safety, efficacy, and accessibility.

Professor Paul Friedman, Chair of Cardiovascular Medicine at Mayo Clinic, also reinforced the vision, pointing to the collaborative endeavor’s potential to deepen insights into disease mechanisms and expand therapeutic options. He emphasized that collaboration across continents and institutions is vital to addressing the multifactorial and heterogeneous nature of cardiovascular disorders in contemporary medicine.

At an operational level, the collaboration will foster joint research projects, encompassing basic science, clinical trials, and population health studies. A particularly exciting avenue involves the validation and popularization of AI-ECG technology, which has the potential to revolutionize routine cardiovascular screening and early diagnosis, ultimately shifting clinical paradigms from reactive to proactive care.

The partnership is further bolstered by support from the Tanoto Foundation, an independent family organization dedicated to catalyzing systemic changes in education, healthcare, and leadership development. Their involvement underscores the social and educational dimensions embedded within the collaboration, aiming not only for scientific breakthroughs but also for sustainable workforce capacity building and health equity.

This collaboration represents a paradigm shift by recognizing the necessity of region-specific data and collaborative innovation in tackling global health challenges. It exemplifies the power of combining detailed population-specific clinical expertise with robust, global research infrastructure, fostering an inclusive and forward-thinking model for cardiovascular science.

As cardiovascular diseases continue to impose significant global health burdens, the NHCS-Mayo Clinic partnership emerges as a beacon of hope, demonstrating how international collaboration, cutting-edge technology, and shared clinical insights can coalesce to redefine cardiovascular care for diverse populations, ultimately moving closer toward the goal of precision medicine on a global scale.

Subject of Research: Cardiovascular innovation and research; cardio-oncology; AI-enabled digital biomarkers; cardiovascular aging and frailty; translational cardiovascular medicine.

Article Title: Accelerating Cardiovascular Innovation: The Strategic Partnership Between National Heart Centre Singapore and Mayo Clinic

News Publication Date: 20 June 2025

Web References:

• SingHEART study: https://www.nhcs.com.sg/research-innovation/nhris/core-themes/Pages/Data-Digital-Technology-AI.aspx
• National Heart Centre Singapore: http://www.nhcs.com.sg

References:

• SingHEART: A national 20-year study on cardiovascular health integrating clinical, imaging, exercise physiology, metabolomic, and genetic data.

Keywords: Cardiovascular disorders; Human heart; Cardiology; Cardio-oncology; Artificial intelligence in medicine; Digital biomarkers; Cardiac imaging; Cardiovascular aging; Frailty; Translational research; Precision medicine; Healthcare innovation.